查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1344273

API 中间体市场：按类型、应用程式和最终用户划分：2023-2032 年全球机会分析和产业预测

API Intermediate Market By Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 390 Pages | 商品交期: 2-3个工作天内

价格

根据Allied Market Research发布的研究报告《API中间体市场》，2022年API中间体市场价值将达到1394亿美元，2023年至2032年复合年增长率为7.4%预计到2032年将成长至2,850亿美元。

API中间市场-IMG1

活性药物成分（API）是用于製造药物的物质或物质组合。 用于配製活性药物成分的原料称为 API 中间体。 API中间体是活性药物成分製造过程中产生的物质。 API中间体有两类：化学中间体和原料药中间体。 原料药中间体是指药品生产过程中所产生的化学物质或化合物。 另一方面，化学中间体是在各种化学品的合成和製造过程中产生的化合物和物质，包括药品、农药、染料、聚合物和其他工业产品。

API中间体市场的成长是由慢性病盛行率上升和老年人口增加所推动的。 原料药及中间体用于治疗肿瘤科、心臟科、中枢神经系统（CNS）及神经科、骨科、肺科、胃肠科、肾臟科、眼科、内分泌科等疾病治疗所使用的优质药品。 活性药物成分和中间体有潜力透过引入更多创新产品来创建更永续的医疗保健系统。 因此，患有心臟病等慢性病的人口不断增加预计将刺激对原料药中间体的需求并推动市场成长。 例如，根据英国心臟基金会的数据，到 2022 年，英国将有大约 1,139,140 人患有心臟和循环系统疾病。 据同一消息来源称，2022 年英国患心臟和循环系统疾病的人数约为 650,681 名男性和 488,320 名女性。

此外，根据美国心臟协会的数据，预计 2020 年将有 2.441 亿人患有缺血性心臟病 (IHD)。 根据相同数据，男性罹患 IHD 的比例高于女性，分别为 1.41 亿和 1.031 亿。

目录

第1章简介

第 2 章执行摘要

第3章市场概述

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 慢性疾病增加
      • 市场公司的影响力较高
      • 老年人口迅速增加
    • 抑制因素
      • 严格的政府法规
    • 机会
      • 生医产业快速成长
      • 市场公司更采用关键策略
  • 新冠肺炎 (COVID-19) 造成的市场影响分析

第 4 章 API 中间体市场：依型别

  • 摘要
  • API中间体
  • 化学中间体

第5章 API 中间体市场：依应用划分

  • 摘要
  • 止痛药
  • 抗感染药物
  • 抗糖尿病药物
  • 心血管药物
  • 抗癌药物
  • 其他

第 6 章 API 中间市场：依最终使用者划分

  • 摘要
  • 生技和製药公司
  • 首席行销长
  • 其他

第 7 章 API 中间体市场：依地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他领域

第8章竞争态势

  • 简介
  • 关键成功策略
  • 10家主要公司的产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022 年主要公司的定位

第9章公司简介

  • Anyang General Chemical Co., Ltd.
  • Sandoo Pharmaceuticals
  • Evonik Industries AG.
  • Shree Ganesh Remedies Limited
  • Cambrex Corporation
  • Zeal & Innovation in Medicine
  • Cation Pharma
  • Espee
  • Hikal Ltd
  • Pfizer Inc.
Product Code: A02308

According to a new report published by Allied Market Research, titled, "API Intermediate Market," The api intermediate market was valued at $139.4 billion in 2022, and is estimated to reach $285 billion by 2032, growing at a CAGR of 7.4% from 2023 to 2032.

API Intermediate Market - IMG1

Active pharmaceutical ingredients (APIs) are substances or combination of substances used to manufacture a drug product. The raw material used in formulation of active pharmaceutical ingredients is known as API intermediates. API intermediates are material produced in the process of manufacturing of API. There are two types of API intermediates, which includes chemical intermediates and bulk drug intermediates. A bulk drug intermediate refers to a chemical substance or compound that is produced during the manufacturing process of a pharmaceutical drug. A chemical intermediate, on the other hand, is a compound or substance that is produced during the synthesis or production of various chemicals, including pharmaceuticals, agrochemicals, dyes, polymers, and other industrial products.

The growth of the API intermediates market is driven by rise in the prevalence of chronic diseases and increase in number of geriatric populations. APIs and intermediates possess application in high-quality drugs used for the treatment of diseases, such as oncology, cardiology, central nervous system (CNS) and neurology, orthopedic, pulmonology, gastroenterology, nephrology, ophthalmology, and endocrinology. APIs and intermediates can potentially create a more sustainable healthcare system by introducing more innovative products. Thus, rise in number of populations suffering from chronic diseases, such as cardiac diseases, is anticipated to fuel the demand for API intermediates and boosts the market growth. For instance, according to the British Heart Foundation, around 1,139,140 people were suffering from heart and circulatory diseases in the UK in 2022. As per the same source, around 650,681 male and 488,320 female population were suffering from heart and circulatory diseases in the UK in 2022.

Moreover, according to the American Heart Association, 244.1 million people were estimated to be living with ischemic heart disease (IHD) in 2020. As per the same source, IHD was more prevalent in males than in females, 141.0 and 103.1 million people, respectively.

In addition, the American Cancer Society reported that, around 1,918,030 new cases of cancer detected in the U.S. in 2022. Moreover, World Cancer Research Fund International, (WCRFI), reported that around 18.1 million new cancer cases were detected in 2020 globally. Furthermore, rise in number of populations suffering from pulmonary and gastrointestinal disorders is expected to increase the demand for API intermediates and fuels the growth of the market. The global initiative for chronic obstructive lung disease (GOLD), in 2022, reported that 200 million people had chronic obstructive pulmonary disease (COPD), of which about 3.2 million die each year, making it the third-leading cause of death globally. In addition, as per the same source, asthma is one of the most common non-communicable diseases, globally affecting 262 million people in 2022.

High presence of companies who manufacture API intermediates is anticipated to boost the growth of the market. For instance, Shubham Specialty Products, Akums Drugs & Pharmaceuticals Ltd., Vasoya Industrial Pvt. Lmt., Corey Organics, Icon Pharma Chem, and SLN Pharmachem are some of the key market players who manufacture API intermediates.

However, the high cost associated with the acquisition of biopharmaceutical drugs is a major factor hampering the growth of global API intermediates market. Also, the high cAPItal investment required to produce API intermediates is expected to restrain the market growth.

On the contrary, rise in initiative taken by government of different countries such as India, China, Japan, and others, for development of healthcare infrastructure and increase in expenditure for development of API intermediates manufacturing units are anticipated to offer remunerative opportunities for the expansion of the market during the forecast period.

The global API intermediates market is segmented into type, application, end user, and region. By type, the market is divided into bulk drug intermediates and chemical intermediates. On the basis of application, the market is divided into analgesics, anti-infective drugs, antidiabetic drugs, cardiovascular drugs, anticancer drugs and others. By end user, the market is segmented into biotech & pharmaceutical companies, CMO and research laboratories. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global API intermediates market include: Anyang General Chemical Co., Ltd., Sandoo Pharmaceuticals, Evonik Industries AG, Shree Ganesh Remedies Limited, Pfizer, Cambrex Corporation, Zeal & Innovation in Medicine, cation pharma, Hikal Ltd., and Espee.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the API intermediate market analysis from 2022 to 2032 to identify the prevailing API intermediate market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the API intermediate market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global API intermediate market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Bulk Drug Intermediates
  • Chemical Intermediates

By Application

  • Analgesics
  • Anti-Infective Drugs
  • Antidiabetic Drugs
  • Cardiovascular Drugs
  • Anticancer Drugs
  • Others

By End User

  • Biotech and Pharmaceutical Companies
  • CMO
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Anyang General Chemical Co., Ltd.
    • Cambrex Corporation
    • Cation Pharma
    • Espee
    • Evonik Industries AG.
    • Hikal Ltd
    • Pfizer Inc.
    • Sandoo Pharmaceuticals
    • Shree Ganesh Remedies Limited
    • Zeal & Innovation in Medicine

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Low bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Low intensity of rivalry
    • 3.3.5. Low bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of chronic disease
      • 3.4.1.2. High presence of market players
      • 3.4.1.3. Surge in number of geriatric populations
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent government rules
    • 3.4.3. Opportunities
      • 3.4.3.1. Rapid growth of biopharmaceutical industry
      • 3.4.3.2. Increase in adoptions of key strategies by market players.
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: API INTERMEDIATE MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Bulk Drug Intermediates
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chemical Intermediates
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: API INTERMEDIATE MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Analgesics
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Anti-Infective Drugs
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Antidiabetic Drugs
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Cardiovascular Drugs
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Anticancer Drugs
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Others
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country

CHAPTER 6: API INTERMEDIATE MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Biotech and Pharmaceutical Companies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. CMO
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: API INTERMEDIATE MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.1.4. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.2.4. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Application
      • 7.2.5.3.4. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.1.4. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.2.4. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.3.4. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.4.4. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.5.4. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Application
      • 7.3.5.6.4. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.1.4. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.2.4. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.3.4. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.4.4. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.5.4. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Application
      • 7.4.5.6.4. Market size and forecast, by End User
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.1.4. Market size and forecast, by End User
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.2.4. Market size and forecast, by End User
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.3.4. Market size and forecast, by End User
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Application
      • 7.5.5.4.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Anyang General Chemical Co., Ltd.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
  • 9.2. Sandoo Pharmaceuticals
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
  • 9.3. Evonik Industries AG.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Shree Ganesh Remedies Limited
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
  • 9.5. Cambrex Corporation
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. Zeal & Innovation in Medicine
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Cation Pharma
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
  • 9.8. Espee
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
  • 9.9. Hikal Ltd
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Pfizer Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. API INTERMEDIATE MARKET FOR BULK DRUG INTERMEDIATES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. API INTERMEDIATE MARKET FOR CHEMICAL INTERMEDIATES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GLOBAL API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 05. API INTERMEDIATE MARKET FOR ANALGESICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. API INTERMEDIATE MARKET FOR ANTI-INFECTIVE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. API INTERMEDIATE MARKET FOR ANTIDIABETIC DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. API INTERMEDIATE MARKET FOR CARDIOVASCULAR DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. API INTERMEDIATE MARKET FOR ANTICANCER DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. API INTERMEDIATE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. API INTERMEDIATE MARKET FOR BIOTECH AND PHARMACEUTICAL COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. API INTERMEDIATE MARKET FOR CMO, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. API INTERMEDIATE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. API INTERMEDIATE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 20. U.S. API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. U.S. API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. CANADA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. CANADA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. CANADA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. UK API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. UK API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 41. UK API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. ITALY API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ITALY API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 44. ITALY API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. CHINA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. CHINA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 60. CHINA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. INDIA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. INDIA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 63. INDIA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 82. SAUDI ARABIA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. ANYANG GENERAL CHEMICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 90. ANYANG GENERAL CHEMICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 91. ANYANG GENERAL CHEMICAL CO., LTD.: PRODUCT SEGMENTS
  • TABLE 92. ANYANG GENERAL CHEMICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 93. SANDOO PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 94. SANDOO PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 95. SANDOO PHARMACEUTICALS: PRODUCT SEGMENTS
  • TABLE 96. SANDOO PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 97. EVONIK INDUSTRIES AG.: KEY EXECUTIVES
  • TABLE 98. EVONIK INDUSTRIES AG.: COMPANY SNAPSHOT
  • TABLE 99. EVONIK INDUSTRIES AG.: PRODUCT SEGMENTS
  • TABLE 100. EVONIK INDUSTRIES AG.: PRODUCT PORTFOLIO
  • TABLE 101. SHREE GANESH REMEDIES LIMITED: KEY EXECUTIVES
  • TABLE 102. SHREE GANESH REMEDIES LIMITED: COMPANY SNAPSHOT
  • TABLE 103. SHREE GANESH REMEDIES LIMITED: PRODUCT SEGMENTS
  • TABLE 104. SHREE GANESH REMEDIES LIMITED: SERVICE SEGMENTS
  • TABLE 105. SHREE GANESH REMEDIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 106. CAMBREX CORPORATION: KEY EXECUTIVES
  • TABLE 107. CAMBREX CORPORATION: COMPANY SNAPSHOT
  • TABLE 108. CAMBREX CORPORATION: PRODUCT SEGMENTS
  • TABLE 109. CAMBREX CORPORATION: SERVICE SEGMENTS
  • TABLE 110. CAMBREX CORPORATION: PRODUCT PORTFOLIO
  • TABLE 111. CAMBREX CORPORATION: KEY STRATERGIES
  • TABLE 112. ZEAL & INNOVATION IN MEDICINE: KEY EXECUTIVES
  • TABLE 113. ZEAL & INNOVATION IN MEDICINE: COMPANY SNAPSHOT
  • TABLE 114. ZEAL & INNOVATION IN MEDICINE: PRODUCT SEGMENTS
  • TABLE 115. ZEAL & INNOVATION IN MEDICINE: PRODUCT PORTFOLIO
  • TABLE 116. CATION PHARMA: KEY EXECUTIVES
  • TABLE 117. CATION PHARMA: COMPANY SNAPSHOT
  • TABLE 118. CATION PHARMA: PRODUCT SEGMENTS
  • TABLE 119. CATION PHARMA: PRODUCT PORTFOLIO
  • TABLE 120. ESPEE: KEY EXECUTIVES
  • TABLE 121. ESPEE: COMPANY SNAPSHOT
  • TABLE 122. ESPEE: PRODUCT SEGMENTS
  • TABLE 123. ESPEE: PRODUCT PORTFOLIO
  • TABLE 124. HIKAL LTD: KEY EXECUTIVES
  • TABLE 125. HIKAL LTD: COMPANY SNAPSHOT
  • TABLE 126. HIKAL LTD: PRODUCT SEGMENTS
  • TABLE 127. HIKAL LTD: PRODUCT PORTFOLIO
  • TABLE 128. PFIZER INC.: KEY EXECUTIVES
  • TABLE 129. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 130. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 131. PFIZER INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. API INTERMEDIATE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF API INTERMEDIATE MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN API INTERMEDIATE MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW INTENSITY OF RIVALRY
  • FIGURE 08. LOW BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALAPI INTERMEDIATE MARKET
  • FIGURE 09. API INTERMEDIATE MARKET, BY TYPE, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR BULK DRUG INTERMEDIATES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR CHEMICAL INTERMEDIATES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. API INTERMEDIATE MARKET, BY APPLICATION, 2022(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR ANALGESICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR ANTI-INFECTIVE DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR ANTIDIABETIC DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR CARDIOVASCULAR DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR ANTICANCER DRUGS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. API INTERMEDIATE MARKET, BY END USER, 2022(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR BIOTECH AND PHARMACEUTICAL COMPANIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR CMO, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. API INTERMEDIATE MARKET BY REGION, 2022
  • FIGURE 24. U.S. API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. AUSTRALIA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SAUDI ARABIA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. SOUTH AFRICA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LAMEA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: API INTERMEDIATE MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2022
  • FIGURE 50. EVONIK INDUSTRIES AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. EVONIK INDUSTRIES AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. EVONIK INDUSTRIES AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)